Patent intelligence · US
US 11548951
Compositions and methods for treatment of thyroid eye disease
Compositions and methods for treatment of thyroid eye disease
Patent details — US 11548951
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 10, 2023
- Expiration
- Jan 5, 2043
- Applicant
- Viridian Therapeutics, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545
Quick answer
US 11548951 (Compositions and methods for treatment of thyroid eye disease) is held by Viridian Therapeutics, Inc.. Status: granted. Granted Jan 10, 2023. Expires Jan 5, 2043 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Viridian Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K9/0019, A61P
More from Viridian Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11548951?
US 11548951 (Compositions and methods for treatment of thyroid eye disease) is held by Viridian Therapeutics, Inc.. Status: granted. Granted Jan 10, 2023. Expires Jan 5, 2043 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11548951?
Viridian Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 11548951 expire?
Our index shows an expiration date of Jan 5, 2043 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.